Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit
Launched by UNIVERSITY OF VALENCIA · Aug 26, 2014
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
Residual neuromuscular block (RNMB) is frequent in the immediate postoperative period and is a source of complications, mainly respiratory. This includes recovery delay or hospital discharge delays, respiratory insufficiency or infections, unforeseen ICU admissions, and prolonged ICU stays.
The incidence is variable due to multiple factors. Age, gender, surgery, NMBA type and doses, temperature, medications, etc.
In several studies it has been found and incidence between 6-80%. Few studies have been focused in evaluating the incidence in the whole country, as representing a global anesthe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients \>18 years-old
- • General anesthesia with non-depolarizing NMBA
- • Transferred extubated on spontaneous ventilation to the PACU
- Exclusion Criteria:
- • American Society of Anesthesiologists physical status IV-V
- • emergency and cardiac surgery
- • patients unable to respond adequately at the moment of pre- or postoperative evaluation (psychiatric diseases, excessive somnolence, agitation, etc.)
- • noncompensated diabetes mellitus or diabetic neuropathy
- • symptomatic severe hypothyroidism (or untreated), or scheduled for total thyroidectomy
- • chronic or acute renal insufficiency
- • severe hepatopathy (Child-Pugh B, C)
- • intraoperative blood transfusion \>3 blood units
- • intraoperative maintained arterial hypotension
- • arrival to the PACU intubated or with instrumented airway (including surgical)
- • pre- or perioperative drugs intake affecting the neuromuscular transmission
- • neuromuscular diseases affecting the physiology of the neuromuscular system
About University Of Valencia
The University of Valencia, a prestigious institution located in Spain, is dedicated to advancing scientific knowledge and improving public health through innovative research. With a strong emphasis on interdisciplinary collaboration, the university engages in a wide array of clinical trials aimed at addressing pressing medical challenges. Its commitment to ethical standards and regulatory compliance ensures the integrity of its research initiatives, while its experienced team of researchers and clinicians work diligently to translate scientific discoveries into practical applications that benefit patients and communities. The University of Valencia is at the forefront of medical research, fostering a culture of excellence and innovation in the pursuit of better healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Zaragoza, , Spain
Madrid, , Spain
Madrid, , Spain
Badalona, Barcelona, Spain
Madrid, , Spain
Santander, , Spain
Valencia, , Spain
Granada, , Spain
Lugo, , Spain
Córdoba, , Spain
Vigo, Pontevedra, Spain
Leganés, Madrid, Spain
Castellón, , Spain
Barcelona, , Spain
Elda, Alicante, Spain
Madrid, , Spain
Valencia, , Spain
Palma De Mallorca, , Spain
Badalona, Barcelona, Spain
A Coruña, Coruña, Spain
Manacor, Palma De Mallorca, Spain
Basurto, Vizcaya, Spain
Logroño, , Spain
Valencia, , Spain
Patients applied
Trial Officials
Carlos L Errando, MD, PhD
Principal Investigator
Servicio de Anestesiologia. Consorcio Hospital General Universitario de Valencia
Ignacio Garutti, MD, PhD
Principal Investigator
Servicio de Anestesiologia. Hospital Universitario Gregorio Marañon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials